Research Disclaimer
This article reviews published scientific literature for educational purposes only. All compounds referenced are sold by Blank Peptides exclusively for in-vitro research and laboratory use. Nothing in this article constitutes medical advice, a treatment recommendation, or an endorsement of human use.
GLP-1 receptor agonists have dominated metabolic research since 2023. With three major compounds now widely available, understanding their differences is essential for designing effective protocols.
Understanding the GLP-1 Receptor System
Glucagon-like peptide-1 (GLP-1) is an incretin hormone produced by intestinal L-cells in response to food intake. It plays a central role in glucose homeostasis through several interconnected mechanisms:
- Insulin secretion — stimulates glucose-dependent insulin release from pancreatic beta cells
- Glucagon suppression — reduces glucagon release, lowering hepatic glucose output
- Gastric emptying — slows transit, extending nutrient absorption time
- Appetite signaling — modulates hypothalamic pathways to reduce food intake
Semaglutide: The GLP-1 Selective Agonist
Semaglutide at a Glance
- Receptor profile: GLP-1 only (mono-agonist)
- Half-life: ~168 hours (7 days)
- Published efficacy: STEP trials — 15–17% mean weight reduction
- Price: $75
Semaglutide is a modified GLP-1 analog with a C-18 fatty acid chain that enables albumin binding, dramatically extending its half-life. This was the compound that catalyzed the current wave of metabolic research interest and remains the most extensively studied GLP-1 agonist.
Research Applications
- Obesity models — appetite suppression via hypothalamic signaling and delayed gastric emptying
- Type 2 diabetes — improved insulin sensitivity with high GLP-1R selectivity
- Cardiovascular risk — established data from large-scale clinical trials
- NASH/MAFLD — moderate impact on hepatic fat accumulation
Tirzepatide: The Dual GLP-1/GIP Agonist
Tirzepatide at a Glance
- Receptor profile: GLP-1 + GIP dual agonist (twincretin)
- Half-life: ~120 hours (5 days)
- Published efficacy: SURMOUNT trials — 20–22% mean weight reduction
- Price: $65
Tirzepatide represents a paradigm shift in incretin research by engaging both GLP-1 and GIP receptors simultaneously. The GIP component adds metabolic effects that GLP-1 alone cannot achieve, particularly in fat tissue metabolism and insulin sensitivity.
Research Applications
- Advanced obesity models — dual mechanism produces effects neither receptor achieves independently
- Lipid metabolism — GIP receptor activation enhances fat oxidation
- Tolerability studies — GIP engagement appears to reduce nausea vs pure GLP-1 agonists
- Comparative protocols — head-to-head studies against semaglutide
Retatrutide: The Triple Agonist
Retatrutide at a Glance
- Receptor profile: GLP-1 + GIP + Glucagon triple agonist
- Half-life: ~168 hours (approximately 7 days)
- Published efficacy: Phase 2 trials — up to 24% mean weight reduction
- Price: $135
Retatrutide adds a third receptor — the glucagon receptor — creating the first triple incretin agonist available for research. The glucagon component introduces direct effects on energy expenditure and hepatic lipid metabolism that dual agonists lack.
Research Applications
- NASH/MAFLD liver research — glucagon receptor activation specifically targets hepatic fat reduction
- Energy expenditure — glucagon component increases basal metabolic rate
- Advanced obesity models — highest efficacy of any incretin compound studied to date
- Multi-receptor pharmacology — broadest receptor engagement for mechanistic studies
Head-to-Head Comparison
| Feature | Semaglutide | Tirzepatide | Retatrutide |
|---|---|---|---|
| Receptors | GLP-1 only | GLP-1 + GIP | GLP-1 + GIP + Glucagon |
| Half-life | ~7 days | ~5 days | ~7 days |
| Weight Reduction | 15–17% | 20–22% | Up to 24% |
| GI Tolerability | Moderate | Better | Variable |
| Liver Fat Impact | Moderate | Moderate-High | Highest |
| Literature Base | Most extensive | Growing rapidly | Early but promising |
| Blank Price | $75 | $65 | $135 |
Which Compound Is Right for Your Research?
Quick Decision Guide
- Choose Semaglutide — if your research builds on established GLP-1 protocols, requires extensive literature support, or focuses on glucose homeostasis and appetite regulation
- Choose Tirzepatide — if you’re investigating additive GIP signaling effects, studying lipid metabolism, or need better tolerability for longer-duration studies
- Choose Retatrutide — if your research targets hepatic steatosis, energy expenditure, or requires the broadest possible receptor engagement
All three compounds are available from Blank Peptides with full third-party COA documentation and research-grade purity verification.
Browse These Compounds